CTRI/2017/12/010798已完成3 期
A Double-blind, Multicentric, Randomized, Parallel Group, Comparative Bioequivalence study with Clinical end-point to evaluate the Efficacy and Safety of Fixed Dose Combination of Clotrimazole 1% w/w plus Hydrocortisone 1% w/w Cream (Test) of Encube Ethicals Pvt. Ltd., India compared with the Canesten HC Cream (Reference) of Bayer PLC, UK for the treatment of fungal skin infection with co-existing symptoms of inflammation. - .
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 209
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Subjects or their legally acceptable representative who are able to provide written, signed, dated and ethics committee approved informed consent form before performing any screening procedures.
- •2.Male and/or female of 18-65 years (both inclusive)
- •3.Subjects with clinical manifestations of localized epidermal dermatophytosis and candidiasis provisionally confirmed at baseline by a microscopic examination of positive potassium hydroxide (KOH) wet mount preparation (i.e., skin scrapings from the target site are placed on a microscope slide with a drop of 10% KOH, and microscopic examination reveals segmented fungal hyphae).
- •4.The sum of the clinical signs and symptoms scores of the target lesion is at least 4, including a minimum score of at least 2 for erythema AND a minimum score of 2 for either scaling or pruritus (on a scale of 0-3, where 2 indicates moderate severity).
- •5.Willingness to comply with the study schedule and procedures.
排除标准
- •1.Known hypersensitivity to clotrimazole or hydrocortisone or any of the excipients in this product.
- •2.Untreated bacterial skin infection such as syphilis or tuberculosis.
- •3.Viral skin diseases (e.g. herpes simplex, chicken pox, etc.)
- •4.Use of oral steroids or immunosuppressive agents within past 30 days.
- •5.Use of antipruritics, including antihistamines, within 772 hours prior to entry into the study.
- •6.Use of topical corticosteroid, antibiotic or antifungal therapy within 2 weeks prior to entry into the study.
- •7.Use of systemic (e.g., oral or injectable) corticosteroid, antibiotic or antifungal therapy within 1 month prior to entry into the study.
- •8.Use of oral terbinafine or itraconazole within 2 months prior to entry into the study.
- •9.Use of immunosuppressive medication or radiation therapy within 3 months prior to entry into the study.
- •10.Confluent, diffuse type fungal skin infection of the entire body surface.
- •11.Presence of any other infection of the skin or other disease process that might confound the treatment evaluation.
- •12.History of dermatophyte infections unresponsive to systemic or topical antifungal drugs.
- •13.Subjects with history of diabetes mellitus and systemic illness.
- •14.Participate in any other clinical study during last 30 days.
- •15.Subject is a female who is pregnant or willing to get pregnant, and not ready to use contraceptive measures during the trial period or breast feeding.
- •16.Any other clinically significant abnormal medical condition that in the Investigators judgment would put the subject at increased risk of illness or injury, would interfere with the study participation or would interfere with the evaluation or quality of the data.
研究者
相似试验
进行中（未招募）
1 期
The purpose of this study is to determine whether CBT124 and Avastin®are comparable in terms of efficacy, safety, immunogenicity; and whether the pharmacokinetics of CBT124 matches that of Avastin®(pharmacokinetics is nested in this study for Indian patients).EUCTR2016-003301-34-BGCipla BioTec Pvt. Ltd.200
尚未招募
3 期
Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel versus DUAC® Gel versus Placebo in Patients with Acne VulgarisCTRI/2015/11/006379Cadila Healthcare Limited850
已完成
不适用
A study to check effectiveness of Adapalene and Benzoyl peroxide Gel in patients with Acne VulgarisCTRI/2019/01/017297Morningside Healthcare Ltd550
进行中（未招募）
1 期
The purpose of this study is to determine whether CBT124 and Avastin®are comparable in terms of efficacy, safety, immunogenicity; and whether the pharmacokinetics of CBT124 matches that of Avastin®(pharmacokinetics is nested in this study for Indian patients).non-squamous Non-Small-Cell-Lung CancerMedDRA version: 19.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-003301-34-HUCipla BioTec Pvt. Ltd.200
Unknown
3 期
Comparison of 5% Spironolactone Topical Cream with Placebo for safety and efficacy in Patients with Acne VulgarisCTRI/2020/05/025476Alkem Laboratories Limited